Business context and reporting period
This is Elevai Labs Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2023. The filing describes Elevai as a skincare company developing, manufacturing, and selling topical products, primarily through physician-dispensed channels. The request metadata names PMGC Holdings Inc., but the filing itself identifies Elevai Labs Inc. (Nasdaq: ELAB) as the registrant.
Financial highlights
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $554,654 | $432,122 | $1,014,004 | $627,379 |
| Gross profit | $366,145 | $237,694 | $672,882 | $353,899 |
| Gross margin | 66% | 55% | 66% | 56% |
| Net loss | $(783,047) | $(499,085) | $(3,143,601) | $(1,147,611) |
| Operating cash flow | Not presented by quarter | Not presented by quarter | $(2,168,661) | $(1,079,472) |
At September 30, 2023, cash was $476,855, current assets were $1,276,604, and current liabilities were $1,643,575, resulting in a $366,971 working-capital deficit. Total liabilities were $1,746,884; these included $519,509 of derivative liabilities and $244,219 of operating lease liabilities. The company reported a total equity deficit of $163,895 and accumulated deficit of $5,865,974. The filing does not report conventional borrowing outstanding at quarter-end.
Material changes versus the prior comparable period
- Nine-month revenue increased $386,625, or about 62%, while gross margin rose from 56% to 66%. Management attributed the margin improvement chiefly to a higher mix of Enfinity and Empower products versus lower-margin white-label sales, and improved Empower and white-label margins.
- Nine-month operating expenses increased $1,887,332 to $3,358,152. The largest increases were office and administration (+$989,217), professional fees (+$355,519), marketing (+$181,674), and R&D (+$135,881). Management cited higher staffing, share-based compensation, IPO-related professional costs, and expanded marketing.
- Nine-month net loss widened by $1,995,990. A $451,054 loss from the change in fair value of derivative liabilities contributed to the 2023 result; management notes this valuation uses Level 3 inputs, including estimated volatility.
- Cash fell by $678,046 from year-end 2022 to $476,855. Operating cash use increased, while financing provided $1,501,085, principally from common-stock and warrant issuances and option exercises.
Outlook, risks, and unusual items
- Going concern: Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing recurring losses, operating cash use, the working-capital deficit, and equity deficit. The filing says continued shareholder support, additional financing, and ultimately profitable operations are important; the financial statements contain no going-concern adjustments.
- Subsequent IPO: After quarter-end, the company sold 1,500,000 shares at $4.00 each in an IPO, generating $6,000,000 gross proceeds before underwriting discounts and offering expenses. Trading began November 21, 2023. The filing states proceeds are intended for general and administrative costs, marketing and market expansion, R&D, and working capital. The IPO occurred after the reported balance-sheet date and does not change the September 30 cash balance.
- Management plans: Over the next twelve months, management intended to expand the sales force, pursue clinical validation studies, develop new formulations, and broaden international distribution. The filing gives no quantified revenue, earnings, or cash-flow guidance.
- Concentrations: The largest customer accounted for 14% of nine-month 2023 revenue, down from 55% in 2022. Three key suppliers represented 66% of inventory purchase and production costs, versus 72% a year earlier.
- Other items: Related-party amounts due were $222,675 at quarter-end. A vendor dispute was settled for approximately $9,225 and paid during the period. Management reported no material pending legal proceeding, no material off-balance-sheet arrangements, and effective disclosure controls; it also reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer identity: this filing is for Elevai Labs Inc., not PMGC Holdings Inc.
- Review the IPO’s net proceeds after offering costs and the company’s subsequent cash, liquidity, and going-concern disclosures.
- Assess the sustainability of revenue growth and gross margins, including product mix, sales commissions, and dependence on key suppliers and distributors.
- Examine the causes and valuation sensitivity of the $519,509 derivative liability and its substantial period-to-period fair-value effect on reported earnings.
- Review dilution from the IPO and outstanding options and warrants; the filing reports 17,329,615 common shares issued and outstanding as of December 11, 2023.